Evrofarma Balance Sheet Health

Financial Health criteria checks 4/6

Evrofarma has a total shareholder equity of €17.6M and total debt of €16.9M, which brings its debt-to-equity ratio to 96.1%. Its total assets and total liabilities are €49.6M and €31.9M respectively. Evrofarma's EBIT is €3.4M making its interest coverage ratio 2.6. It has cash and short-term investments of €470.0K.

Key information

96.1%

Debt to equity ratio

€16.95m

Debt

Interest coverage ratio2.6x
Cash€470.00k
Equity€17.63m
Total liabilities€31.93m
Total assets€49.56m

Recent financial health updates

Recent updates

A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price

Dec 19
A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price

Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Oct 02
Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Feb 29
Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Jan 06
Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Jan 05
Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Dec 01
Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Sep 15
Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

May 27
Is Evrofarma (ATH:EVROF) Using Too Much Debt?

We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Oct 04
We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

May 19
Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Feb 22
Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Dec 29
Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Nov 22
Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Financial Position Analysis

Short Term Liabilities: EVROF's short term assets (€19.0M) exceed its short term liabilities (€13.8M).

Long Term Liabilities: EVROF's short term assets (€19.0M) exceed its long term liabilities (€18.1M).


Debt to Equity History and Analysis

Debt Level: EVROF's net debt to equity ratio (93.5%) is considered high.

Reducing Debt: EVROF's debt to equity ratio has reduced from 149% to 96.1% over the past 5 years.

Debt Coverage: EVROF's debt is well covered by operating cash flow (28%).

Interest Coverage: EVROF's interest payments on its debt are not well covered by EBIT (2.6x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 07:25
End of Day Share Price 2025/01/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evrofarma SA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution